Repligen Corporation has announced its financial results for the third quarter of 2026, revealing a significant revenue increase and an optimistic outlook for the remainder of the year. The company reported revenues of $209 million, an 11% increase compared to the same period last year. This growth comes alongside the successful completion of its acquisition of BioLife Solutions, which is expected to enhance Repligen's offerings in the rapidly growing cell therapy market.

Olivier Loeillot, President and CEO of Repligen, expressed confidence in the company's performance, stating, "We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book." Loeillot also highlighted the positive feedback from customers regarding the BioLife acquisition and the progress made in integrating the two companies.

The filing, dated October 27, 2026, reveals that Repligen is raising its full-year revenue guidance to between $844 million and $852 million, which represents a reported growth of 14.5% to 15.5%. This optimistic projection reflects the company's strong performance thus far and the anticipated benefits from the BioLife acquisition.

Background

Repligen Corporation, incorporated in Delaware, operates in the biological products sector, specifically focusing on biological products without diagnostic substances (SIC 2836). The company trades on the Nasdaq under the ticker symbol RGEN. Recent filings include an 8-K dated October 27, 2026, detailing its financial results and an earlier filing on October 6, 2026, regarding other corporate matters.

What the Filing Says

According to the filing, "On October 27, 2026, Repligen Corporation announced its financial results for the third quarter ended September 30, 2026." The document also notes that the press release related to these results is attached as Exhibit 99.1. The company reported a revenue of $209 million for Q3, which is an 11% increase year-over-year.

Impact

This update is significant not only for Repligen but also for the broader biological products industry. The successful integration of BioLife Solutions is expected to enhance Repligen's competitive edge, potentially impacting other players in the market. The raised revenue guidance signals confidence in continued growth, which may influence investor sentiment and competitive strategies among peers.

What's Next

The filing does not specify what happens next, but the raised guidance and strong performance suggest that Repligen will continue to focus on integrating BioLife Solutions and expanding its market presence.